Switch theme
Sign up to access all valuation multiples
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
1999
16
LTM Revenue $61.7M
LTM EBITDA $31.7M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clinuvel Pharma has a last 12-month revenue of $61.7M and a last 12-month EBITDA of $31.7M.
In the most recent fiscal year, Clinuvel Pharma achieved revenue of $55.8M and an EBITDA of $35.6M.
Clinuvel Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clinuvel Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $49.5M | $55.8M | XXX | XXX | XXX |
| Gross Profit | $34.9M | $44.0M | XXX | XXX | XXX |
| Gross Margin | 71% | 79% | XXX | XXX | XXX |
| EBITDA | $31.3M | $35.6M | XXX | XXX | XXX |
| EBITDA Margin | 63% | 64% | XXX | XXX | XXX |
| Net Profit | $13.2M | $19.4M | XXX | XXX | XXX |
| Net Margin | 27% | 35% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Clinuvel Pharma's stock price is AUD 12 (or $7).
Clinuvel Pharma has current market cap of AUD 577M (or $365M), and EV of AUD 380M (or $240M).
See Clinuvel Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $365M | XXX | XXX | XXX | XXX | $0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Clinuvel Pharma has market cap of $365M and EV of $240M.
Clinuvel Pharma's trades at 3.9x LTM EV/Revenue multiple, and 7.6x LTM EBITDA.
Analysts estimate Clinuvel Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Clinuvel Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $240M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 7.0x | XXX | XXX | XXX |
| P/E | 15.5x | XXX | XXX | XXX |
| P/E/Growth | 1.8x | XXX | XXX | XXX |
| EV/FCF | 10.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpClinuvel Pharma's NTM/LTM revenue growth is 6%
Clinuvel Pharma's revenue per employee for the last fiscal year averaged $3.5M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Clinuvel Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Clinuvel Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Clinuvel Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 58% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 64% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $3.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clinuvel Pharma acquired XXX companies to date.
Last acquisition by Clinuvel Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Clinuvel Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Clinuvel Pharma founded? | Clinuvel Pharma was founded in 1999. |
| Where is Clinuvel Pharma headquartered? | Clinuvel Pharma is headquartered in Australia. |
| How many employees does Clinuvel Pharma have? | As of today, Clinuvel Pharma has 16 employees. |
| Who is the CEO of Clinuvel Pharma? | Clinuvel Pharma's CEO is Dr. Philippe J. Wolgen, M.B.A.,M.D.. |
| Is Clinuvel Pharma publicy listed? | Yes, Clinuvel Pharma is a public company listed on ASX. |
| What is the stock symbol of Clinuvel Pharma? | Clinuvel Pharma trades under CUV ticker. |
| When did Clinuvel Pharma go public? | Clinuvel Pharma went public in 2001. |
| Who are competitors of Clinuvel Pharma? | Similar companies to Clinuvel Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Clinuvel Pharma? | Clinuvel Pharma's current market cap is $365M |
| What is the current revenue of Clinuvel Pharma? | Clinuvel Pharma's last 12-month revenue is $61.7M. |
| What is the current EBITDA of Clinuvel Pharma? | Clinuvel Pharma's last 12-month EBITDA is $31.7M. |
| What is the current EV/Revenue multiple of Clinuvel Pharma? | Current revenue multiple of Clinuvel Pharma is 3.9x. |
| What is the current EV/EBITDA multiple of Clinuvel Pharma? | Current EBITDA multiple of Clinuvel Pharma is 7.6x. |
| What is the current revenue growth of Clinuvel Pharma? | Clinuvel Pharma revenue growth between 2023 and 2024 was 13%. |
| Is Clinuvel Pharma profitable? | Yes, Clinuvel Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
